Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immunoglobulin kappa variable 1-39 (IGKV1-39) encodes the V (variable) region of the kappa light chain in immunoglobulins (antibodies)[5][10][3]. This region forms part of the antigen binding site and contributes molecular diversity through V(D)J recombination and somatic hypermutation, which are essential for adaptive immune response and specificity[5][10][3]. The variable region of the kappa light chain, paired with the variable region of the heavy chain, determines the specificity of antibody–antigen interactions. The IGKV1-39 gene is present in the genome but does not produce a functional protein by itself; rather, it contributes to antibody diversity in B-cells via genetic rearrangement mechanisms[2][5]. Various alternative names reflect historical isolates of immunoglobulin light chains with IGKV1-39 sequence characteristics, often associated with certain monoclonal gammopathies or as research reagents[2][5][9]. IGKV1-39 is not a druggable therapeutic target, enzyme, transporter, or receptor, but is a critical genetic component of antibody variable regions and crucial for humoral immunity[7][10][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Immunoglobulin kappa variable 1-39 (IGKV1-39).